Brief: Grand Pharmaceutical Says Phase III Clinical Trial Application Of GPN00833 Got Implied NMPA Approval
12/04/2023 11:21
April 12 (Reuters) - Grand Pharmaceutical Group Ltd
0512.HK :
* PHASE III CLINICAL TRIAL APPLICATION OF GPN00833 OBTAINED
IMPLIED APPROVAL FROM NMPA
Further company coverage: 0512.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grand Pharmaceutical
See all newsBrief: Grand Pharmaceutical Group Declares No Interim Dividend Has Been Paid
Grand Pharmaceutical H1 revenue rises on nuclear medicine demand
Grand Pharma rises most in over a year as drug gets US FDA fast track designation
GPN01530-2 Granted Fast Track Designation By FDA
Brief: Grand Pharmaceutical Group Enters Huadong Medicine Supply Agreement